Gadolinium is a commonly used contrast agent for myocardial infarction during CMR examinations, but its nephrotoxicity and short examination time window limited its application to some extent. We try to develop new contrast agents with superior imaging performance and good biocompatibility, which can achieve clinical translation.
This abstract and the presentation materials are available to members only; a login is required.